sFIDA for Subvisible Particle Analysis

About Attyloid

Founded in 2018 as an academic spin-off from Forschungszentrum Jülich, Attyloid is dedicated to advancing the molecular understanding of protein misfolding diseases. Its core sFIDA technology enables the detection of biomarkers at unprecedented sensitivity across various biological matrices, including blood, CSF, and even stool. The company's work is pivotal for CNS biomarker development, drug efficacy testing, and has been featured in high-profile clinical trials and peer-reviewed publications.

Therapeutic Areas